KRAS and non-small cell lung carcinoma: In early-phase studies, particularly the KRYSTAL-1 phase 1/2 trial, adagrasib demonstrated deep and durable responses, with promising progression-free survival (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated NSCLC, also including patients with untreated brain metastases [56,57].